Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Mitigating smoldering myeloma progression risk

Sagar Lonial • 17 Jun 2020
EHA 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma Carfilzomib Dexamethasone Lenalidomide

Sagar Lonial, MD, of Winship Cancer Institute of Emory University, Atlanta, GA, discusses new insights on smoldering myeloma and the risk of progression into multiple myeloma. Specifically discussed is the identification of patients that have a higher likelihood of progression based on genetic markers and how this can be used to inform treatment approaches. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sagar Lonial

1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
0:45
The addition of daratumumab to RVD deepens treatment responses in t(11;14) multiple myeloma
Sagar Lonial • 9 Dec 2023
1:06
DeRIVE trial update: DId vs DVd in newly diagnosed MM
Sagar Lonial • 9 Dec 2023
0:48
Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma
Sagar Lonial • 7 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals